Trial Condition(s):

Relapsing-Remitting Multiple Sclerosis

Injection management with Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Bayer Identifier:

14543

ClinicalTrials.gov Identifier:

NCT00902135

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron. The Personal digital assistant PDA functions as an electronic diary and as an injection reminder.

Inclusion Criteria
- Outpatients with the diagnosis of Multiple Sclerosis and decision by the investigator to prescribe Betaferon.The decision for treatment type and duration is taken before offering the patient the possibility to participate in the study.
Exclusion Criteria
- Patients, who do not meet the Clinically Isolated Syndrome (CIS) or Relapsing/Remitting Multiple Sclerosis (RRMS) criteria, should not be included. 
 - Exclusion criteria must be read in conjunction with the German product information.

Trial Summary

Enrollment Goal
702
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 

Trial Design